Treatment of Clostridioides difficile Infection
For initial C. difficile infection, fidaxomicin 200 mg twice daily for 10 days is the preferred treatment, with vancomycin 125 mg four times daily for 10 days as an acceptable alternative 1.
Initial Episode Treatment Algorithm
The 2021 IDSA/SHEA guidelines provide clear treatment stratification based on disease severity:
Non-Severe to Moderate CDI
- First-line: Fidaxomicin 200 mg PO twice daily × 10 days 1
- Alternative: Vancomycin 125 mg PO four times daily × 10 days 1
- Last resort (only if above unavailable): Metronidazole 500 mg PO three times daily × 10-14 days 1
Important caveat: Metronidazole should only be used for non-severe CDI (defined as WBC ≤15,000 cells/μL AND serum creatinine <1.5 mg/dL) when fidaxomicin and vancomycin are unavailable 1. This represents a major shift from older guidelines—metronidazole is no longer considered first-line therapy due to inferior outcomes and resistance concerns 2, 3.
Fulminant CDI
For patients with hypotension/shock, ileus, or megacolon 1:
- Vancomycin 500 mg PO or NG four times daily (note the higher dose)
- PLUS IV metronidazole 500 mg every 8 hours 1
- If ileus present: Add rectal vancomycin instillation 1
This is a medical emergency requiring aggressive treatment and early surgical consultation 3.
Recurrent CDI Management
First Recurrence
- Preferred: Fidaxomicin 200 mg twice daily × 10 days, OR extended regimen (twice daily × 5 days, then every other day × 20 days) 1
- Alternative: Vancomycin tapered and pulsed regimen (125 mg four times daily × 10-14 days, then twice daily × 7 days, then once daily × 7 days, then every 2-3 days × 2-8 weeks) 1
- Adjunctive therapy: Consider bezlotoxumab 10 mg/kg IV once during antibiotic treatment 1
Critical consideration: If metronidazole was used for the initial episode, use a standard vancomycin course rather than continuing metronidazole 1.
Second or Subsequent Recurrence
Multiple options exist 1:
- Fidaxomicin (standard or extended regimen)
- Vancomycin tapered/pulsed regimen
- Vancomycin 125 mg four times daily × 10 days followed by rifaximin 400 mg three times daily × 20 days
- Fecal microbiota transplantation (FMT) after at least 2 recurrences (i.e., 3 total CDI episodes) 1
FMT safety alert: The FDA has issued multiple warnings about transmission of pathogenic organisms (including fatal E. coli infections) and potential SARS-CoV-2 transmission through FMT 1. Appropriate donor and specimen screening is mandatory.
Key Evidence Considerations
The European guidelines (2021) similarly prioritize fidaxomicin over metronidazole and emphasize risk stratification for recurrence rather than just severity 2. Recent data from a 2026 randomized trial suggests that extended vancomycin tapers (4 weeks vs 2 weeks) may reduce early recurrence, with a 99% probability of superiority at day 38 4.
Bezlotoxumab warning: Use with caution in patients with congestive heart failure—the FDA recommends reserving it for cases where benefits outweigh risks 1.
Common Pitfalls to Avoid
- Don't use metronidazole as first-line unless fidaxomicin and vancomycin are truly unavailable
- Don't delay surgical consultation in fulminant cases—mortality can reach 20% with certain ribotypes 3
- Don't forget to discontinue the inciting antibiotic and proton pump inhibitors when possible 5
- Don't offer FMT prematurely—at least 2 recurrences should be treated with appropriate antibiotics first 1
- Don't use IV vancomycin alone—it doesn't achieve adequate colonic concentrations; oral/rectal routes are essential 1